Sanofi at a glance

Available and open to EU residents only.

Sanofi: Our Company Picture

About Sanofi

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, we transform scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutics solutions focused on patients' needs. Sanofi is organized into five global business units: Sanofi Genzyme, Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Pasteur and Merial. 

  • Based in Paris, France
  • Present in more that 100 countries
  • 110,000 employees globally
  • Revenues of €35,055M in 2017
  • €5,472 million 2017 investment in R&D

Sanofi A Life Sciences Company

About Sanofi Genzyme

Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology.

  • Based in Cambridge, MA, USA
  • 3,000+ employees globally
  • Revenues of €5,674M in 2017
     


SANOFI GENZYME, RESEARCHING NEW TREATMENTS IN IMMUNOLOGY

Immunology is an area of growth for Sanofi Genzyme and an area in which we hope to make a significant difference in patients’ lives. In collaboration with Regeneron, we are researching and developing two new therapies.

The first therapy under review is for the treatment of rheumatoid arthritis, a chronic and painful inflammatory disorder that damages the joints.


Elizabeth, Atopic Dermatitis Patient - USA
 

The second is a new therapy under investigation for atopic dermatitis, a devastating autoimmune disorder affecting the skin. We are also studying other allergic and respiratory diseases, including asthma and nasal polyposis.
 


Sanofi Genzyme Europe highlights 2017

  • Business in 38 countries and 8 MCOs (Multi-country organization)
  • 20 marketed products
  • 2 new launches
  • 1,742 employees
  • 4,900 treated patients in Rare Diseases
  • 55,000 treated patients in MS on Sanofi Genzyme Therapies
  • Around 43,000 treated patients in onco - hematology diseases (prostate, colorectal, transplants)

 


Sanofi Earnings 2017

© 2016 Genzyme Europe B.V. - All rights reserved. 

This website is intended for Sales & Marketing professionals based in Europe

Last updated: 26/02/2018